NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Cantor Fitzgerald Virtual Heathcare Conference 2020 – PowerPoint Presentation
To download the presentation, Click Here
STRO-002 Shows Early Efficacy, Safety in Heavily Pretreated Epithelial Ovarian Cancer – OncLive September 2020
The novel anti-folate receptor alpha antibody-drug conjugate STRO-002 demonstrated encouraging efficacy with a tolerable safety profile in patients with advanced platinum-resistant or refractory epithelial ovarian cancer. The novel anti-folate receptor alpha (FolRα)...
International Gynecologic Cancer Society (IGCS) Virtual Healthcare Conference 2020 – Poster
Phase 1 Dose-Escalation Study of STRO-002, An Anti-Folate Receptor Alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum-Resistant/Refractory Epithelial Ovarian Cancer (OC)
Investor Conference Call September 9, 2020 – Presentation
To download the presentation, Click Here
Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting
Updated Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression Conference Call Today Scheduled for 5:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 – Sutro...
Sutro Biopharma to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting
Ongoing Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression Conference Call Scheduled for Sept 9, 2020 at 5:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 2, 2020...
IGCS 2020 Annual Global Meeting – Abstract
Phase 1 Dose-Escalation Study of STRO-002, an anti-Folate Receptor alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum Resistant/Refractory Epithelial Ovarian Cancer (OC). Dr. Naumann is currently the Director of Minimally Invasive Surgery in...
Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
SOUTH SAN FRANCISCO, Calif., August 25, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Announces Two Executive Promotions to Vice President of Quality and Vice President of Manufacturing
Mr. Carlos Lugo promoted to Vice President of Quality and CMC Regulatory Operations Mr. Devendra Luhar promoted to Vice President of Manufacturing & Plant Operations SOUTH SAN FRANCISCO, Calif., August 11, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...